Bioventus (NASDAQ:BVS) Shares Up 5.1% – Should You Buy?

Bioventus Inc. (NASDAQ:BVS)’s share price shot up 5.1% on Wednesday . The company traded as high as $8.59 and last traded at $8.52. 291,690 shares traded hands during trading, a decline of 31% from the average session volume of 423,999 shares. The stock had previously closed at $8.11.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Craig Hallum lifted their target price on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Barrington Research restated an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a report on Friday, May 22nd. CJS Securities started coverage on shares of Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Bioventus has an average rating of “Buy” and an average target price of $14.00.

Bioventus Stock Up 3.9%

The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. The company’s fifty day simple moving average is $9.65 and its 200 day simple moving average is $8.54. The firm has a market capitalization of $704.24 million, a PE ratio of 20.56, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.09 by $0.06. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. The business had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Analysts anticipate that Bioventus Inc. will post 0.77 earnings per share for the current fiscal year.

Insider Buying and Selling at Bioventus

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the transaction, the director owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 33.00% of the company’s stock.

Hedge Funds Weigh In On Bioventus

Institutional investors and hedge funds have recently made changes to their positions in the business. Anderson Financial Strategies LLC bought a new position in shares of Bioventus during the third quarter valued at approximately $901,000. Royce & Associates LP increased its position in shares of Bioventus by 15.6% during the third quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock valued at $8,449,000 after acquiring an additional 170,900 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of Bioventus during the fourth quarter valued at approximately $2,008,000. Legato Capital Management LLC increased its position in shares of Bioventus by 1,042.8% during the fourth quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock valued at $1,023,000 after acquiring an additional 125,525 shares in the last quarter. Finally, Eversept Partners LP increased its position in shares of Bioventus by 8.6% during the fourth quarter. Eversept Partners LP now owns 471,257 shares of the company’s stock valued at $3,506,000 after acquiring an additional 37,324 shares in the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.